(Q40000217)

English

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

phase I clinical trial

0 references

multiple sclerosis

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Lei Diao

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yaming Hang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Ivan Nestorov

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jonathan Q Tran

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

1 August 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

55

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

943-955

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26873229%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

https://scigraph.springernature.com/pub.10.1007/s40262-016-0366-7

0 references

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0366-7

21 January 2018

The biology of interleukin-2.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0366-7

21 January 2018

Interleukin-2, interleukin-15, and their receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0366-7

21 January 2018

Daclizumab (anti-CD25) in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0366-7

21 January 2018

Emerging injectable therapies for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0366-7

21 January 2018

Immunological differences between classical phenothypes of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0366-7

21 January 2018

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0366-7

21 January 2018

Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0366-7

21 January 2018

Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0366-7

21 January 2018

Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0366-7

21 January 2018

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26873229

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26873229

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/26873229

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40000217&oldid=2143797707"